Ginkgo Bioworks Holdings (DNA) Other Operating Expenses (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Other Operating Expenses came in at -$7.1 million in Q1 2026, down 54.1% YoY from -$15.6 million in Q1 2025, and down 57.87% on a QoQ basis from -$4.5 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Other Operating Expenses (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Other Operating Expenses data on file, last reported at -$7.1 million in Q1 2026.
- Quarterly Other Operating Expenses fell 54.1% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.6 million (down 278.27% YoY) and the FY2025 annual result came in at -$4.5 million, down 216.98% from the prior year.
- Other Operating Expenses declined to -$7.1 million in Q1 2026, from -$4.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $10.9 million in Q4 2024 to a low of -$7.1 million in Q1 2026.
- A 5-year average of $829250.0 and a median of $901000.0 in 2022 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2024 — Other Operating Expenses jumped 11602.15% — and 2025, when it sank 330.17%.
- Tracing DNA's Other Operating Expenses over 5 years: stood at $6.2 million in 2022, then sank by 98.49% to $93000.0 in 2023, then jumped by 11602.15% to $10.9 million in 2024, then plunged by 141.6% to -$4.5 million in 2025, then tumbled by 57.87% to -$7.1 million in 2026.
- The last three Other Operating Expenses figures came in at -$7.1 million (Q1 2026), -$4.5 million (Q4 2025), and -$896000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 809,000.00 |
| Mar 31, 2026 | -7.15 Mn |
| Dec 31, 2025 | -4.53 Mn |
| Jun 30, 2025 | -896,000.00 |
| Mar 31, 2025 | -4.64 Mn |
| Dec 31, 2024 | 10.88 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | -766,000.00 |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 93,000.00 |
| Sep 30, 2023 | 2.89 Mn |
| Jun 30, 2023 | 3.22 Mn |
| Mar 31, 2023 | 2.93 Mn |
| Dec 31, 2022 | 6.16 Mn |
| Sep 30, 2022 | -676,000.00 |
| Jun 30, 2022 | 230,000.00 |
| Mar 31, 2022 | 1.92 Mn |
| Dec 31, 2021 | -2.60 Mn |
| Sep 30, 2021 | -4.91 Mn |
| Jun 30, 2021 | 7.12 Mn |